Refuse To Accept Procedures for Premarket Tobacco Product Submissions; Revised Effective Date, 8894 [2017-02174]
Download as PDF
<![CDATA[
8894
Federal Register / Vol. 82, No. 20 / Wednesday, February 1, 2017 / Rules and Regulations
effective date for this action to give DOC
officials the opportunity to further
review and consider the revision,
consistent with the Memorandum. The
rule published November 25 containing
the revision was exempt from notice
and comment because it involved a
military and foreign affairs function of
the United States (See 5 U.S.C.
553(a)(1)). Given the imminence of the
new effective date, seeking prior public
comment on this temporary delay
would be impractical, unnecessary, and
also contrary to the public interest in
the orderly promulgation and
implementation of regulations.
Dated: January 27, 2017.
Matthew S. Borman,
Deputy Assistant Secretary for Export
Administration.
[FR Doc. 2017–02164 Filed 1–31–17; 8:45 am]
BILLING CODE 3510–33–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1105
[Docket No. FDA–2016–N–1555]
Refuse To Accept Procedures for
Premarket Tobacco Product
Submissions; Revised Effective Date
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule; delay of effective
date.
In accordance with the
memorandum of January 20, 2017, from
the Assistant to the President and Chief
of Staff, entitled ‘‘Regulatory Freeze
Pending Review,’’ this action revises the
effective date of the final rule (‘‘Refuse
to Accept Procedures for Premarket
Tobacco Product Submissions’’)
published December 29, 2016, from
January 30, 2017, until March 21, 2017.
DATES: The effective date of the rule that
published on December 29, 2016, at 81
FR 95863, is delayed until March 21,
2017.
SUMMARY:
pmangrum on DSK3GDR082PROD with RULES
FOR FURTHER INFORMATION CONTACT:
Center for Tobacco Products, Food and
Drug Administration, 10903 New
Hampshire Ave., Document Control
Center, Bldg. 71, Rm. G335, Silver
Spring, MD 20993–0002, email:
AskCTP@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
December 29, 2016, the Food and Drug
Administration (FDA or Agency) issued
a final rule describing when FDA will
refuse to accept a tobacco product
VerDate Sep<11>2014
15:00 Jan 31, 2017
Jkt 241001
submission (or application) because the
application has not met a minimum
threshold for acceptability for FDA
review (81 FR 95863). Under the rule,
FDA will refuse to accept a tobacco
product submission, for example, that is
not in English, does not pertain to a
tobacco product, or does not identify the
type of submission. The rule was
published with an effective date of
January 30, 2017.
FDA bases this action on the
memorandum of January 20, 2017 (82
FR 8346), from the Assistant to the
President and Chief of Staff, entitled
‘‘Regulatory Freeze Pending Review.’’
That memorandum directed the heads
of Executive Departments and Agencies
to temporarily postpone for 60 days
from the date of the memorandum the
effective dates of all regulations that had
been published in the Federal Register
but had not yet taken effect, for the
purpose of ‘‘reviewing questions of fact,
law, and policy they raise.’’ FDA,
therefore, is revising the effective date of
the rule that published on December 29,
2016 (81 FR 95863), to March 21, 2017.
To the extent that 5 U.S.C. 553 applies
to this action, it is exempt from notice
and comment because it constitutes a
rule of procedure under 5 U.S.C.
553(b)(A). Alternatively, the Agency’s
implementation of this action without
opportunity for public comment,
effective immediately upon publication
today in the Federal Register, is based
on the good cause exceptions in 5 U.S.C.
553(b)(B) and (d)(3). Seeking public
comment is impracticable, unnecessary,
and contrary to the public interest. The
temporary delay in the effective date
until March 21, 2017, is necessary to
give Agency officials the opportunity for
further review and consideration of the
new regulation, consistent with the
memorandum described previously.
Given the imminence of the effective
date and the brief length of the
extension of the effective date, seeking
prior public comment on this temporary
delay would have been impracticable, as
well as contrary to the public interest in
the orderly promulgation and
implementation of regulations.1 FDA
also believes that affected entities need
to be informed as soon as possible of the
extension and its length in order to plan
and adjust their implementation process
accordingly.
1 In the event that this rule does not publish on
or before January 30, 2017, good cause similarly
exists to stay the effectiveness of the rule published
December 29, 2016, and revise its effective date
until March 21, 2017.
PO 00000
Frm 00002
Fmt 4700
Sfmt 4700
Dated: January 27, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–02174 Filed 1–30–17; 11:15 am]
BILLING CODE 4164–01–P
DEPARTMENT OF JUSTICE
28 CFR Part 31
[Docket No.: OJP (OJJDP) 1719E]
RIN 1121–AA83
Juvenile Justice and Delinquency
Prevention Act Formula Grant Program
Office of Justice Programs,
Department of Justice.
ACTION: Final rule; delay of effective
date.
AGENCY:
On January 17, 2017, the
Office of Juvenile Justice and
Delinquency Prevention (‘‘OJJDP’’) of
the U.S. Department of Justice’s Office
of Justice Programs (‘‘OJP’’), published a
partial final rule to amend portions of
the formula grant program (‘‘Formula
Grant Program’’) regulation to reflect
changes in OJJDP policy. That rule is
scheduled to become effective February
16, 2017.
In accordance with the memorandum
of January 20, 2017, from the Assistant
to the President and Chief of Staff,
entitled ‘‘Regulatory Freeze Pending
Review,’’ this action hereby temporarily
delays the effective date of the final rule
entitled ‘‘Juvenile Justice and
Delinquency Prevention Act Formula
Grant Program’’ until March 21, 2017
(which is 60 days from January 20,
2017). This temporary delay will allow
Department of Justice officials an
opportunity to review any potential
questions of fact, law and policy raised
by this regulation, consistent with the
Chief of Staff’s memorandum of January
20, 2017.
DATES: This rule is effective February 1,
2017. The effective date of the final rule
amending 28 CFR part 31 published in
the Federal Register on January 17,
2017, at 82 FR 4783, is delayed to March
21, 2017.
FOR FURTHER INFORMATION CONTACT: Mr.
Gregory Thompson, Senior Advisor,
Office of Juvenile Justice and
Delinquency Prevention, at 202–307–
5911.
SUMMARY:
The OJJDP
Formula Grant Program is authorized by
the Juvenile Justice and Delinquency
Prevention Act (‘‘JJDPA’’). The JJDPA
authorizes OJJDP to provide an annual
grant to each State to improve its
juvenile justice system and to support
SUPPLEMENTARY INFORMATION:
E:\FR\FM\01FER1.SGM
01FER1
]]>Agencies
[Federal Register Volume 82, Number 20 (Wednesday, February 1, 2017)]
[Rules and Regulations]
[Page 8894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02174]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1105
[Docket No. FDA-2016-N-1555]
Refuse To Accept Procedures for Premarket Tobacco Product
Submissions; Revised Effective Date
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; delay of effective date.
-----------------------------------------------------------------------
SUMMARY: In accordance with the memorandum of January 20, 2017, from
the Assistant to the President and Chief of Staff, entitled
``Regulatory Freeze Pending Review,'' this action revises the effective
date of the final rule (``Refuse to Accept Procedures for Premarket
Tobacco Product Submissions'') published December 29, 2016, from
January 30, 2017, until March 21, 2017.
DATES: The effective date of the rule that published on December 29,
2016, at 81 FR 95863, is delayed until March 21, 2017.
FOR FURTHER INFORMATION CONTACT: Center for Tobacco Products, Food and
Drug Administration, 10903 New Hampshire Ave., Document Control Center,
Bldg. 71, Rm. G335, Silver Spring, MD 20993-0002, email:
AskCTP@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On December 29, 2016, the Food and Drug
Administration (FDA or Agency) issued a final rule describing when FDA
will refuse to accept a tobacco product submission (or application)
because the application has not met a minimum threshold for
acceptability for FDA review (81 FR 95863). Under the rule, FDA will
refuse to accept a tobacco product submission, for example, that is not
in English, does not pertain to a tobacco product, or does not identify
the type of submission. The rule was published with an effective date
of January 30, 2017.
FDA bases this action on the memorandum of January 20, 2017 (82 FR
8346), from the Assistant to the President and Chief of Staff, entitled
``Regulatory Freeze Pending Review.'' That memorandum directed the
heads of Executive Departments and Agencies to temporarily postpone for
60 days from the date of the memorandum the effective dates of all
regulations that had been published in the Federal Register but had not
yet taken effect, for the purpose of ``reviewing questions of fact,
law, and policy they raise.'' FDA, therefore, is revising the effective
date of the rule that published on December 29, 2016 (81 FR 95863), to
March 21, 2017.
To the extent that 5 U.S.C. 553 applies to this action, it is
exempt from notice and comment because it constitutes a rule of
procedure under 5 U.S.C. 553(b)(A). Alternatively, the Agency's
implementation of this action without opportunity for public comment,
effective immediately upon publication today in the Federal Register,
is based on the good cause exceptions in 5 U.S.C. 553(b)(B) and (d)(3).
Seeking public comment is impracticable, unnecessary, and contrary to
the public interest. The temporary delay in the effective date until
March 21, 2017, is necessary to give Agency officials the opportunity
for further review and consideration of the new regulation, consistent
with the memorandum described previously. Given the imminence of the
effective date and the brief length of the extension of the effective
date, seeking prior public comment on this temporary delay would have
been impracticable, as well as contrary to the public interest in the
orderly promulgation and implementation of regulations.\1\ FDA also
believes that affected entities need to be informed as soon as possible
of the extension and its length in order to plan and adjust their
implementation process accordingly.
---------------------------------------------------------------------------
\1\ In the event that this rule does not publish on or before
January 30, 2017, good cause similarly exists to stay the
effectiveness of the rule published December 29, 2016, and revise
its effective date until March 21, 2017.
Dated: January 27, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-02174 Filed 1-30-17; 11:15 am]
BILLING CODE 4164-01-P
